Basilea studies show promising drug-drug interaction, antifungal activity of BAL 8557

By Lisa Kerner

Charlotte, N.C., June 27 - Basilea Pharmaceutica Ltd. said studies show its antifungal BAL8557 has a promising drug-drug interaction profile and broad-spectrum antifungal activity.

BAL8557 had no significant impact on the pharmacokinetics of the immunosuppressant drug ciclosporin, a relatively modest effect on tacrolimus and no effect on the kinetics of the anticoagulant drug warfarin.

The company is presenting the data in five clinical posters at the International Society for Human and Animal Mycology meeting in Paris.

Two oral presentations will discuss clinical phase 2 safety results and on in vitro activity toward resistant Histoplasma capsulatum.

"BAL8557 has the potential to be a leading antifungal drug for the treatment of severe invasive fungal infections with its intravenous and oral formulations, a broad-spectrum and a promising drug-drug interaction profile," chief development officer Rienk Pypstra said in a company news release.

"Because of its potential to fulfill high medical needs unmet by current therapies, BAL8557 was recently granted Food and Drug Administration fast track designation."

Basilea is an independent biopharmaceutical company with headquarters in Basel, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.